UCB Announces Divestment of Celltech Manufacturing Services - a UCB Subsidiary for Contract Manufacturing
Brussels, Belgium, August 26, 2005 - UCB today announces the divestment of Celltech Manufacturing Services Ltd, in Ashton, UK, a UCB subsidiary carrying out contract manufacturing. The subsidiary has been acquired by US company Inyx Incorporated for 27.5 million Euros. Inyx is a speciality pharmaceutical company focusing on niche drug delivery technologies.
UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex(TM) (antitussive) and Metadate(TM) / Equasym XL(TM) (attention-deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels with a market capitalization of approximately € 6.8 billion.
For enquiries, please contact:
Corporate Communication & Investor Relations
Phone +32 2 559 9588
Fax +32 2 559 9571
Stay up-to-date on the latest news and information from UCB